Successful treatment of refractory childhood vesiculobullous disorders with rituximab: A study of five cases

Buch, Jeta; Raval, Ranjan C

doi:10.4103/2319-7250.175664

Cited by 6 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab has been liberally used in the treatment of adult refractory vesiculobullous disorders, with the recent upsurge in its use among the pediatric population. [ 3 4 5 6 7 8 9 ] Buch et al . [ 6 ] reported five childhood cases of vesiculobullous disorders (3: pemphigus vulgaris, 1: pemphigus foliaceous, and 1: CBDC) who maintained complete remission during the 6 months of follow-up period, along with a decline in the serum anti-DSG titers.…”

Section: Discussionmentioning

confidence: 99%

“…[ 3 4 5 6 7 8 9 ] Buch et al . [ 6 ] reported five childhood cases of vesiculobullous disorders (3: pemphigus vulgaris, 1: pemphigus foliaceous, and 1: CBDC) who maintained complete remission during the 6 months of follow-up period, along with a decline in the serum anti-DSG titers.…”

Section: Discussionmentioning

confidence: 99%

“…Overall 35 reported cases of pemphigus vulgaris have been treated with Rituximab, of which 15 of them were below 12 years of age, the youngest being a 2-year-old infant (erythrodermic pemphigus foliaceous). [ 3 5 6 7 8 9 ]…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of a Refractory Case of Chronic Bullous Disease of Childhood in a Five Year Old Child with Rituximab

Agarwal

Randhawa

Singh

et al. 2021

Indian Dermatology Online Journal

View full text Add to dashboard Cite

Patients with chronic bullous disease of childhood (CBDC) generally respond well to treatment with drugs like Dapsone and oral and topical steroids. Refractory cases are additionally treated with immunosuppressants like azathioprine, methotrexate, ciclosporin, colchicine, tetracycline, and IVIG (Intravenous Immunoglobulin). However, there are few patients who fail to respond to these therapies and pose a challenge both to the patient and the treating physician. Rituximab has been used widely to treat pemphigus cases in adults, but its use in children has not been much reported. We hereby report a case of a 5-year-old child with CBDC, refractory to other treatments, who responded favorably to Rituximab.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of a Refractory Case of Chronic Bullous Disease of Childhood in a Five Year Old Child with Rituximab

Agarwal

Randhawa

Singh

et al. 2021

Indian Dermatology Online Journal

View full text Add to dashboard Cite

show abstract

“…Although PF has been well described in adults, it is a rare disorder in adolescents. We conducted a comprehensive search of the literature through PubMed, and since 2001, only four other cases of juvenile PF treated with rituximab have been described [14,15]. Our patient is the fifth reported case of juvenile PF treated with rituximab (Table 1).…”

Section: Case Discussionmentioning

confidence: 99%

“…A search of the literature revealed that the first reports of rituximab usage in pemphigus were published in 2001. Therefore, only cases of juvenile PF treated with rituximab in 2001 or later were included in this review [14,15]. We defined juvenile PF as cases in which disease was diagnosed between the ages of 12-17.…”

Section: Introductionmentioning

confidence: 99%